JournalArta
Friday, November 20, 2026 · JakartaS&P 7,175.83 ▼2.02%USD/IDR 18,268 ▲0.06%
JournalArta
Global Edition
beyond headlines
Advertisement

Merck (MRK) Stock Slides 3.61% on Thursday, Down 9.6% in Five Sessions

Technical analysis of MRK stock on November 19, 2026: price 132.81 USD, trend downtrend, RSI 31.7, support 132.81, resistance 150.36.

By Elena Vance
WIB5 min read
Merck (MRK) Stock Slides 3.61% on Thursday, Down 9.6% in Five Sessions
Logo Merck — JournalArta illustration

Why MRK is in focus today

  • One-day move of 0.00%, about 0.0× its average daily range (ATR)

Selected automatically from 11 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

A death cross just landed under Merck, and international readers should care because the US drugmaker is a bellwether for defensive healthcare exposure — and right now the technicals are screaming caution. On the New York Stock Exchange session of Thursday, November 19, 2026, Merck (MRK) closed at $132.81, down -3.61% on the day, -9.62% over five sessions and -9.80% across a month. The stock sits at the very bottom of its 20-day range — 0% of the way from support to resistance — while the broader signal count is lopsided: zero bullish signals against three bearish ones.
Advertisement

Trend & Price Action

The structural picture is unambiguous. Merck trades below both its 20-day average of $144.93 and its 50-day average of $145.48, and those two averages have just crossed: a death cross formed one session before the latest close, with the 20-day average slicing beneath the 50-day. That configuration is the textbook marker of a short-term trend turning against a longer one, and it is not a one-off blip — the 20-day average itself fell 0.98% over the past five sessions, confirming a downtrend rather than a flat consolidation.
Price action chart of MRK
3-month price action chart of MRK: price, SMA20/50, Bollinger, support & resistance.
The price is pressed against the 20-day support shelf at $132.81, which doubles as the latest close, while the three-month low sits just below at $131.36. The three-month high of $156.92 is now a distant memory. What matters here is positioning: a close at the floor of the range with a fresh bearish average crossover means sellers, not buyers, are setting the marginal price.
Advertisement

Oscillators & Momentum

Momentum readings confirm the trend rather than fighting it. The RSI(14) at 31.7 is technically "neutral" by the label but is hugging the oversold threshold of 30 — close enough that a reflex bounce is possible, though not evidence of a reversal. The Stochastic oscillator is more emphatic: %K at 6.6 and %D at 7.4, deeply oversold territory where selling pressure has been relentless.
Momentum chart of MRK
Momentum chart of MRK: RSI(14), MACD, Stochastic.
The MACD tells the same story with more weight. At -1.608 against a signal line of -0.270, the histogram is -1.337 — a wide, negative gap that indicates downside momentum is accelerating, not fading. A deeply oversold stochastic alongside a widening negative MACD histogram is a classic "falling knife" signature: the market is stretched, but it has not yet shown the exhaustion that precedes a durable turn.
Advertisement

Volatility & Volume

Volatility is mid-range, which sharpens the message. ATR(14) stands at $4.36, or 3.3% of the price — moderate, not a panic regime — and Bollinger band width is 11.7%, described as normal. Yet the latest close has pushed %B to -22%, meaning price has closed below the lower band at $136.47. In plain terms: the squeeze has resolved downward, and the stock is trading outside its normal statistical envelope. Volume backs the move. The last session saw 13,593,500 shares change hands, about 1.5× the 20-day average of 9,187,375, and On-Balance Volume is falling. Heavy volume on a decline with deteriorating OBV is participation confirming the direction — distribution, not accumulation. One note on the selection signal: the day's move measured 0.00% against roughly 0.0× the average daily range, a flat daily range after the prior slide, which in context reads as a pause inside a downtrend rather than a base.
Advertisement

Fundamental Context

The filings offer a counterweight worth stating plainly. According to its SEC filing, Merck reported quarterly revenue of $18.09 billion for the quarter ended September 30, 2026, up 4.7% from $17.28 billion a year earlier. Net income was $5.07 billion versus $5.79 billion a year prior, with diluted earnings per share of $2.04. Revenue is growing while profit is compressing — a mix the market has clearly priced as a negative, given the price action. Merck also filed a Form 8-K on November 18, 2026, reporting a change of directors or officers, a governance event that lands in the middle of a technical breakdown.

Key Levels & Scenarios

The lines to watch are tight. Resistance sits at $150.36, the 20-day high; support is the $132.81 shelf now acting as the last line before the $131.36 three-month low. If price breaks decisively below $131.36, the path of least resistance opens lower with no nearby technical floor from the data. If the $132.81 shelf holds and buyers absorb the oversold stochastic, the first meaningful test is the lower Bollinger band at $136.47 — reclaiming it would be the earliest sign the downside momentum is stalling. Until then, every bounce is a countertrend move.
Advertisement

Technical Verdict: SELL

The verdict is SELL, backed by a computed score of -84 on a −100 to +100 scale (the model flags a sell at −60 or below), with three bearish drivers against zero bullish: the fresh death cross, the Bollinger squeeze resolved with a close below the lower band, and a downtrend confirmed by falling OBV. Price below the 50-day average and a 20-day average beneath the 50-day seal the case. - Sell zone: $132.81 – $136.08 - Exit target 1: $121.67 | Exit target 2: $110.52 - Stop loss: $140.24 (above the lower band, protecting against a squeeze reversal) - Reward/risk: 1.5 / 3.0 | Valid until December 18, 2026 The call is invalidated if price breaks above the stop at $140.24, which would signal the oversold stochastic at 6.6 has produced a genuine reversal rather than a pause. In plain English: Merck is trending down on heavy volume with no confirmed bottom, and the charts favor staying defensive until the $132.81 floor either breaks or decisively holds. The next scheduled catalyst is the December 18, 2026 validity date on the current setup — the deadline by which the sell thesis either plays out toward $121.67 or expires. This is technical analysis based on exchange data and company filings, not an investment recommendation.
Advertisement

Summary Data MRK

Last price132.81 USD
Change 1 day / 5 days / 1 month-3.61% / -9.62% / -9.80%
Trend / MA-crossdowntrend / death
SMA20 / SMA50144.93 / 145.48
RSI (14) / Stochastic %K31.7 / 6.6
Bollinger %B / ATR-22% / 4.36
Support / Resistance 20 days132.81 / 150.36
Data as of20 November 2026 04:03 WIB
JournalArta research verdict (score)Sell (-84)
Sell zone132.81 – 136.08
Target 1 / 2121.67 / 110.52
Stop loss140.24
Reward/risk1.5 / 3.0

Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Stock Market Today: Dow Slides 1.34% and VIX Jumps 15% at MiddayStock Market Today: Dow Slides 1.34% and VIX Jumps 15% at Midday
  2. 2Joachim Klement to Sell Stocks After S&P 500 SignalJoachim Klement to Sell Stocks After S&P 500 Signal
  3. 3Kenneth Walker’s Groin Injury Puts Cardinals Game in DoubtKenneth Walker’s Groin Injury Puts Cardinals Game in Doubt
  4. 4Pat Cummins Faces Captaincy Doubts From Mitchell JohnsonPat Cummins Faces Captaincy Doubts From Mitchell Johnson
  5. 5McDonald’s Workers’ Discrimination Claims Can Go AheadMcDonald’s Workers’ Discrimination Claims Can Go Ahead
Advertisement
Don't Miss

Latest News

All stories →
  1. UK NCSC Passkeys and Cyber Essentials v3.3: Enterprise PlaybookTechnology · Apps & SoftwareUK NCSC Passkeys and Cyber Essentials v3.3: Enterprise PlaybookNov 20
  2. Daryl Maguire Jailed for Three Years Over Visa FraudWorld · AustraliaDaryl Maguire Jailed for Three Years Over Visa FraudNov 20
  3. Finnish Study Backs Blood Test for Advanced Fatty Liver DiseaseLifestyle · Food & HealthFinnish Study Backs Blood Test for Advanced Fatty Liver DiseaseNov 20
  4. JPMorgan Chase (JPM) Stock Falls 1.20%: Near a 3-Month LowMarkets · StocksJPMorgan Chase (JPM) Stock Falls 1.20%: Near a 3-Month LowNov 20
  5. Advertisement
  6. Anthropic Faces Protests After $2 Trillion Market DebutTechnologyAnthropic Faces Protests After $2 Trillion Market DebutNov 20
  7. UK CMA Cloud & Microsoft SMS Probe: Egress and Licensing ImpactTechnology · Apps & SoftwareUK CMA Cloud & Microsoft SMS Probe: Egress and Licensing ImpactNov 20
  8. Lifestyle Campers Enters Voluntary LiquidationBusiness · CompaniesLifestyle Campers Enters Voluntary LiquidationNov 20
  9. Dow Sinks 1,101 Points as AI Shares Fall After Anthropic DebutMarkets · StocksDow Sinks 1,101 Points as AI Shares Fall After Anthropic DebutNov 20